STTK Stock — Shattuck Labs Inc

Shattuck Labs Inc (STTK)

Updated October 16, 2026.

STTK is a Stock. Total return is -72.0% over the past 6 years, 210.6 points behind SPY at 138.6%.

Shattuck Labs is a clinical-stage biotechnology company developing monoclonal antibodies and related therapies for inflammatory and immune-mediated diseases, with lead programs including SL-325 and SL-425 targeting death receptor 3, along with preclinical bispecific antibodies and an oncology program. The company does not currently distribute to shareholders. Shattuck Labs appeals to investors seeking exposure to early-stage biotech development, where returns depend on clinical trial progress and regulatory approval rather than current income.

STTK performance versus SPY

Price and return data through 2026-10-16.

Total return is -72.0% over the past 6 years, 210.6 points behind SPY at 138.6%. Over the past year its total return — price change plus distributions reinvested — is 201.1%. Its deepest 1-year drawdown was 50.5%.

STTK key facts

Asset type

Stock

Asset class

Equity

Inception date

10/09/2020

Distribution frequency

None

Last close

$5.42 (as of 2026-10-16)

Market cap

$543,968,831

Average volume

648464.0

Beta

1.097

Payout ratio

0.0%

EPS

$-0.46

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

STTK risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 50.5%.

Who may consider STTK — and who may not

It is a weaker fit for investors who need monthly cash flow (STTK does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on STTK

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions